An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Imago BioSciences Announces Oral Data Presentations at the Upcoming 63rd American Society of Hematology Annual Meeting and Exposition
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Imago BioSciences, Inc. (NASDAQ: IMGO) announced that two abstracts related to its LSD1 inhibitor, Bomedemstat (IMG-7289), have been accepted for oral presentations at the 63rd American Society of Hematology Annual Meeting, scheduled for December 11-14, 2021. The first presentation focuses on a Phase 2 study targeting advanced myelofibrosis, while the second addresses essential thrombocythemia. Bomedemstat is currently in two Phase 2 trials and has received FDA Orphan Drug and Fast Track Designation, along with EMA Orphan Designation.
Positive
Acceptance of two abstracts for oral presentations at ASH 2021 highlights clinical interest in Bomedemstat.
Bomedemstat is undergoing two Phase 2 trials, indicating ongoing development and potential market opportunities.
The compound has received multiple designations (FDA Orphan Drug, Fast Track, EMA Orphan Designation, PRIME) that may accelerate its path to market.
Negative
None.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Imago BioSciences, Inc. (Imago) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced two abstracts have been accepted for oral presentation at the 63rdAmerican Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 11-14, 2021.
ASH 2021 Presentation Details:
Oral Presentation Title: “A Phase 2 Study of the LSD1 Inhibitor IMG-7289 (Bomedemstat) for the Treatment of Advanced Myelofibrosis”
Session Name: Myeloproliferative Syndromes: Clinical and Epidemiological: Non-JAK inhibitor Therapies for Myelofibrosis
Presentation Date/Time:December 11, 2021, at 12:00 PM ET Location: Georgia World Congress Center, A411-A412
Oral Presentation Title: “A Phase 2 Study of the LSD1 Inhibitor IMG-7289 (Bomedemstat) for the Treatment of Essential Thrombocythemia (ET)”
Session Name: Myeloproliferative Syndromes: Clinical and Epidemiological: Novel Therapies for MPNs and JAK inhibitors for Myelofibrosis
Presentation Date/Time:Sunday, December 12, 2021, at 9:45 AM ET Location: Georgia World Congress Center, Hall C1
Abstracts are available on the ASH meeting website at www.hematology.org.
About Imago BioSciences
Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency (EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines (PRIME) Designation by the EMA for the treatment of MF. The company is based in South San Francisco, California.
What presentations will Imago BioSciences showcase at ASH 2021?
Imago BioSciences will present two Phase 2 studies of its LSD1 inhibitor Bomedemstat for advanced myelofibrosis and essential thrombocythemia at the ASH Annual Meeting.
When are the Imago BioSciences presentations scheduled at the ASH Annual Meeting?
The presentations are scheduled for December 11, 2021, at 12:00 PM ET, and December 12, 2021, at 9:45 AM ET.
What is Bomedemstat and its significance for Imago BioSciences?
Bomedemstat is an LSD1 inhibitor being evaluated as a potentially disease-modifying therapy for myeloproliferative neoplasms, showing promise in clinical trials.
Which designations has Imago BioSciences received for Bomedemstat?
Bomedemstat has received FDA Orphan Drug and Fast Track Designation, EMA Orphan Designation, and PRIME Designation by the EMA.
Where will the ASH 2021 presentations take place?
The presentations will take place at the Georgia World Congress Center.
